drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic drug), IV infusion
drug_description
Humanized IgG1 anti-CD20 monoclonal antibody administered by IV infusion; depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing B–T cell crosstalk, B-cell cytokine production, and pathogenic humoral responses while largely sparing plasma cells and hematopoietic stem cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ocrelizumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes naïve and memory B cells via ADCC, complement-dependent cytotoxicity, and apoptosis; this reduces antigen presentation, B–T cell crosstalk, B‑cell cytokine production, and pathogenic humoral responses while largely sparing plasma cells and hematopoietic stem cells.
drug_name
Ocrelizumab (Ocrevus)
nct_id_drug_ref
NCT05999604